Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Arthropod Born Viral Infections Market by Test Type (Cultural tests, Immunoassays, Molecular tests, Others) and by End User (Hospitals, Research centers, Diagnostic centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A10480

Pages: NA

Charts: NA

Tables: NA

Arboviral disease is a general term used to describe infections caused by a group of viruses spread among humans by the bite of infected arthropods (insects) such as mosquitoes and ticks; for instance, California encephalitis, Chikungunya, dengue, Eastern equine encephalitis, Powassan, St. Louis encephalitis, West Nile, Yellow Fever, and Zika. Other diseases spread by the bite of infected arthropods that are not viral infections, such as Lyme disease, which is a bacterial infection, and babesiosis, which is a parasitic infection, are not arboviral. The onset of these infections is witnessed during warm weather months, when mosquitoes and ticks are active.. Young children and the elderly appear to be most susceptible to arboviral infection. People who travel to or reside in areas where certain arboviruses are commonly found are at increased risk of acquiring an arboviral infection.

COVID-19 scenario analysis

Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak, from supporting the development of vaccines to scheduling medicines supply chain challenges. Around 115 vaccine candidates and other 155 molecules are in the R&D pipeline. Furthermore, the commonly used drugs, such as hydroxychloroquine, have observed huge boost in demand for the management of COVID-19. In addition, increase has been experienced in the demand for COVID-19 management drugs, which is expected to offer potential opportunity for manufacturers of drugs, as many developed countries are short of these drugs. Owing to the growing demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.

Top impacting factors: market scenario analysis, trends, drivers, and impact analysis

The major factor affecting the arthropod born viral infections market include increase in the prevalence of several arbovirus disorders. This would help the market to gain traction over the next few years. Furthermore, increase in healthcare expenditure is anticipated to boost the market in the coming years. However, lack of awareness regarding the infectious diseases may hinder the growth of the arthropod born viral infections market over the forecast period.

Rise in incidence of encephalitis

The steep increase in the number of incidences of encephalitis would help the arthropod born viral infections market to flourish in the forecast period. According to the estimates given by the World Health Organization in 2019, Japanese encephalitis virus (JEV) is one of the major causes of viral encephalitis in various countries of Asia, and is estimated to cause 68,000 clinical cases every year. Furthermore, the fatality rate among those with encephalitis can be observed to be as high as 30%. In addition to this, there can be other side effects of the JEV, which include permanent neurologic or psychiatric sequelae. This may occur in about 30–50% of the patient population. Thus, growth in the patient population of encephalitis may propel the growth of the market in the coming years.

Surge in number of product launches for diagnostics of the disease

Increase in the number of molecular diagnostic techniques to identify the infection is anticipated to help the arthropod born viral infections market boost in the coming years. For instance, in October 2019, Co-Diagnostics, Inc. announced that the diagnostic method for the identification of the encephalitis virus will be ready in 2020. This is a Biotech company having a patented platform for the development of the molecular diagnostic tests. The test for eastern equine encephalitis (EEE) is stated to get ready in the next mosquito season, which is during 2020. Increase in R&D to develop diagnostic methods for the identification of potential encephalitis virus is expected to gain the attention of the majority of the civil population, and hence the awareness toward the encephalitis virus tends to increase. This is expected to help the market to gain traction in the next few years.

Key benefits of the report:

  • This study presents the analytical depiction of the global arthropod born viral infections industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global arthropod born viral infections market share.
  • The current market is quantitatively analyzed to highlight the global arthropod born viral infections market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the arthropod born viral infections market .
  • The report provides a detailed global arthropod-born viral infections market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the arthropod born viral infections market research report:

  • Which are the leading players active in the arthropod born viral infections market?
  • What are the current trends that will influence the arthropod born viral infections market in the next few years?
  • What are the driving factors, restraints, and opportunities of the arthropod born viral infections market ?
  • What are the projections for the future that would help in tasking further strategic steps?

Key Market Segments

  • By Test Type
    • Cultural tests
    • Immunoassays
    • Molecular tests
    • Others
  • By End User
    • Hospitals
    • Research centers
    • Diagnostic centers
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA


Key Market Players

  • Diste.
  • Copley Scientific,
  • Fluke Biomedical,
  • Agilent Technologies,
  • AESKU.GROUP,
  • BioMed,
  • Acmas Technologie,
  • Datrend System,
  • Ahlborn,
  • Bio-Rad,
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: ARTHROPOD BORN VIRAL INFECTIONS MARKET, BY TEST TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Test Type

    • 4.2. Cultural Tests

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Immunoassays

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Molecular Tests

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: ARTHROPOD BORN VIRAL INFECTIONS MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Research Centers

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Diagnostic Centers

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: ARTHROPOD BORN VIRAL INFECTIONS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Test Type

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Arthropod Born Viral Infections Market

        • 6.2.5.1. Market Size and Forecast, By Test Type
        • 6.2.5.2. Market Size and Forecast, By End User
      • 6.2.6. Canada Arthropod Born Viral Infections Market

        • 6.2.6.1. Market Size and Forecast, By Test Type
        • 6.2.6.2. Market Size and Forecast, By End User
      • 6.2.7. Mexico Arthropod Born Viral Infections Market

        • 6.2.7.1. Market Size and Forecast, By Test Type
        • 6.2.7.2. Market Size and Forecast, By End User
    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Test Type

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Arthropod Born Viral Infections Market

        • 6.3.5.1. Market Size and Forecast, By Test Type
        • 6.3.5.2. Market Size and Forecast, By End User
      • 6.3.6. Germany Arthropod Born Viral Infections Market

        • 6.3.6.1. Market Size and Forecast, By Test Type
        • 6.3.6.2. Market Size and Forecast, By End User
      • 6.3.7. Italy Arthropod Born Viral Infections Market

        • 6.3.7.1. Market Size and Forecast, By Test Type
        • 6.3.7.2. Market Size and Forecast, By End User
      • 6.3.8. Spain Arthropod Born Viral Infections Market

        • 6.3.8.1. Market Size and Forecast, By Test Type
        • 6.3.8.2. Market Size and Forecast, By End User
      • 6.3.9. UK Arthropod Born Viral Infections Market

        • 6.3.9.1. Market Size and Forecast, By Test Type
        • 6.3.9.2. Market Size and Forecast, By End User
      • 6.3.10. Russia Arthropod Born Viral Infections Market

        • 6.3.10.1. Market Size and Forecast, By Test Type
        • 6.3.10.2. Market Size and Forecast, By End User
      • 6.3.11. Rest Of Europe Arthropod Born Viral Infections Market

        • 6.3.11.1. Market Size and Forecast, By Test Type
        • 6.3.11.2. Market Size and Forecast, By End User
    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Test Type

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Arthropod Born Viral Infections Market

        • 6.4.5.1. Market Size and Forecast, By Test Type
        • 6.4.5.2. Market Size and Forecast, By End User
      • 6.4.6. Japan Arthropod Born Viral Infections Market

        • 6.4.6.1. Market Size and Forecast, By Test Type
        • 6.4.6.2. Market Size and Forecast, By End User
      • 6.4.7. India Arthropod Born Viral Infections Market

        • 6.4.7.1. Market Size and Forecast, By Test Type
        • 6.4.7.2. Market Size and Forecast, By End User
      • 6.4.8. South Korea Arthropod Born Viral Infections Market

        • 6.4.8.1. Market Size and Forecast, By Test Type
        • 6.4.8.2. Market Size and Forecast, By End User
      • 6.4.9. Australia Arthropod Born Viral Infections Market

        • 6.4.9.1. Market Size and Forecast, By Test Type
        • 6.4.9.2. Market Size and Forecast, By End User
      • 6.4.10. Thailand Arthropod Born Viral Infections Market

        • 6.4.10.1. Market Size and Forecast, By Test Type
        • 6.4.10.2. Market Size and Forecast, By End User
      • 6.4.11. Malaysia Arthropod Born Viral Infections Market

        • 6.4.11.1. Market Size and Forecast, By Test Type
        • 6.4.11.2. Market Size and Forecast, By End User
      • 6.4.12. Indonesia Arthropod Born Viral Infections Market

        • 6.4.12.1. Market Size and Forecast, By Test Type
        • 6.4.12.2. Market Size and Forecast, By End User
      • 6.4.13. Rest of Asia Pacific Arthropod Born Viral Infections Market

        • 6.4.13.1. Market Size and Forecast, By Test Type
        • 6.4.13.2. Market Size and Forecast, By End User
    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Test Type

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Arthropod Born Viral Infections Market

        • 6.5.5.1. Market Size and Forecast, By Test Type
        • 6.5.5.2. Market Size and Forecast, By End User
      • 6.5.6. South Africa Arthropod Born Viral Infections Market

        • 6.5.6.1. Market Size and Forecast, By Test Type
        • 6.5.6.2. Market Size and Forecast, By End User
      • 6.5.7. Saudi Arabia Arthropod Born Viral Infections Market

        • 6.5.7.1. Market Size and Forecast, By Test Type
        • 6.5.7.2. Market Size and Forecast, By End User
      • 6.5.8. UAE Arthropod Born Viral Infections Market

        • 6.5.8.1. Market Size and Forecast, By Test Type
        • 6.5.8.2. Market Size and Forecast, By End User
      • 6.5.9. Argentina Arthropod Born Viral Infections Market

        • 6.5.9.1. Market Size and Forecast, By Test Type
        • 6.5.9.2. Market Size and Forecast, By End User
      • 6.5.10. Rest of LAMEA Arthropod Born Viral Infections Market

        • 6.5.10.1. Market Size and Forecast, By Test Type
        • 6.5.10.2. Market Size and Forecast, By End User
  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Bio-Rad,

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Copley Scientific,

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Acmas Technologie,

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Fluke Biomedical,

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Datrend System,

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Agilent Technologies,

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Ahlborn,

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. AESKU.GROUP,

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. BioMed,

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Diste.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR CULTURAL TESTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR IMMUNOASSAYS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR MOLECULAR TESTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR RESEARCH CENTERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA ARTHROPOD BORN VIRAL INFECTIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 15. U.S. ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 16. U.S. ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 17. CANADA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 18. CANADA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 20. MEXICO ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE ARTHROPOD BORN VIRAL INFECTIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 25. FRANCE ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 27. GERMANY ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 28. ITALY ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 29. ITALY ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 31. SPAIN ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 32. UK ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 33. UK ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 35. RUSSIA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 37. REST OF EUROPE ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC ARTHROPOD BORN VIRAL INFECTIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 41. CHINA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 42. CHINA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 44. JAPAN ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. INDIA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 46. INDIA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 48. SOUTH KOREA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 50. AUSTRALIA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 52. THAILAND ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 54. MALAYSIA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 56. INDONESIA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA ARTHROPOD BORN VIRAL INFECTIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 63. BRAZIL ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH AFRICA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 67. SAUDI ARABIA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. UAE ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 69. UAE ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 71. ARGENTINA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA ARTHROPOD BORN VIRAL INFECTIONS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 73. REST OF LAMEA ARTHROPOD BORN VIRAL INFECTIONS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. BIO-RAD,: KEY EXECUTIVES
  • TABLE 75. BIO-RAD,: COMPANY SNAPSHOT
  • TABLE 76. BIO-RAD,: OPERATING SEGMENTS
  • TABLE 77. BIO-RAD,: PRODUCT PORTFOLIO
  • TABLE 78. BIO-RAD,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. COPLEY SCIENTIFIC,: KEY EXECUTIVES
  • TABLE 80. COPLEY SCIENTIFIC,: COMPANY SNAPSHOT
  • TABLE 81. COPLEY SCIENTIFIC,: OPERATING SEGMENTS
  • TABLE 82. COPLEY SCIENTIFIC,: PRODUCT PORTFOLIO
  • TABLE 83. COPLEY SCIENTIFIC,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. ACMAS TECHNOLOGIE,: KEY EXECUTIVES
  • TABLE 85. ACMAS TECHNOLOGIE,: COMPANY SNAPSHOT
  • TABLE 86. ACMAS TECHNOLOGIE,: OPERATING SEGMENTS
  • TABLE 87. ACMAS TECHNOLOGIE,: PRODUCT PORTFOLIO
  • TABLE 88. ACMAS TECHNOLOGIE,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. FLUKE BIOMEDICAL,: KEY EXECUTIVES
  • TABLE 90. FLUKE BIOMEDICAL,: COMPANY SNAPSHOT
  • TABLE 91. FLUKE BIOMEDICAL,: OPERATING SEGMENTS
  • TABLE 92. FLUKE BIOMEDICAL,: PRODUCT PORTFOLIO
  • TABLE 93. FLUKE BIOMEDICAL,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. DATREND SYSTEM,: KEY EXECUTIVES
  • TABLE 95. DATREND SYSTEM,: COMPANY SNAPSHOT
  • TABLE 96. DATREND SYSTEM,: OPERATING SEGMENTS
  • TABLE 97. DATREND SYSTEM,: PRODUCT PORTFOLIO
  • TABLE 98. DATREND SYSTEM,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. AGILENT TECHNOLOGIES,: KEY EXECUTIVES
  • TABLE 100. AGILENT TECHNOLOGIES,: COMPANY SNAPSHOT
  • TABLE 101. AGILENT TECHNOLOGIES,: OPERATING SEGMENTS
  • TABLE 102. AGILENT TECHNOLOGIES,: PRODUCT PORTFOLIO
  • TABLE 103. AGILENT TECHNOLOGIES,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. AHLBORN,: KEY EXECUTIVES
  • TABLE 105. AHLBORN,: COMPANY SNAPSHOT
  • TABLE 106. AHLBORN,: OPERATING SEGMENTS
  • TABLE 107. AHLBORN,: PRODUCT PORTFOLIO
  • TABLE 108. AHLBORN,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. AESKU.GROUP,: KEY EXECUTIVES
  • TABLE 110. AESKU.GROUP,: COMPANY SNAPSHOT
  • TABLE 111. AESKU.GROUP,: OPERATING SEGMENTS
  • TABLE 112. AESKU.GROUP,: PRODUCT PORTFOLIO
  • TABLE 113. AESKU.GROUP,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. BIOMED,: KEY EXECUTIVES
  • TABLE 115. BIOMED,: COMPANY SNAPSHOT
  • TABLE 116. BIOMED,: OPERATING SEGMENTS
  • TABLE 117. BIOMED,: PRODUCT PORTFOLIO
  • TABLE 118. BIOMED,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. DISTE.: KEY EXECUTIVES
  • TABLE 120. DISTE.: COMPANY SNAPSHOT
  • TABLE 121. DISTE.: OPERATING SEGMENTS
  • TABLE 122. DISTE.: PRODUCT PORTFOLIO
  • TABLE 123. DISTE.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ARTHROPOD BORN VIRAL INFECTIONS MARKET
  • FIGURE 3. SEGMENTATION ARTHROPOD BORN VIRAL INFECTIONS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ARTHROPOD BORN VIRAL INFECTIONS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALARTHROPOD BORN VIRAL INFECTIONS MARKET
  • FIGURE 11. ARTHROPOD BORN VIRAL INFECTIONS MARKET SEGMENTATION, BY BY TEST TYPE
  • FIGURE 12. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR CULTURAL TESTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR MOLECULAR TESTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. ARTHROPOD BORN VIRAL INFECTIONS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 17. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR RESEARCH CENTERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. ARTHROPOD BORN VIRAL INFECTIONS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: ARTHROPOD BORN VIRAL INFECTIONS MARKET
  • FIGURE 27. TOP PLAYER POSITIONING, 2024
  • FIGURE 28. BIO-RAD,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. BIO-RAD,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. BIO-RAD,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. COPLEY SCIENTIFIC,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. COPLEY SCIENTIFIC,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. COPLEY SCIENTIFIC,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. ACMAS TECHNOLOGIE,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. ACMAS TECHNOLOGIE,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. ACMAS TECHNOLOGIE,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. FLUKE BIOMEDICAL,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. FLUKE BIOMEDICAL,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. FLUKE BIOMEDICAL,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. DATREND SYSTEM,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. DATREND SYSTEM,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. DATREND SYSTEM,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. AGILENT TECHNOLOGIES,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. AGILENT TECHNOLOGIES,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. AGILENT TECHNOLOGIES,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. AHLBORN,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. AHLBORN,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. AHLBORN,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. AESKU.GROUP,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. AESKU.GROUP,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. AESKU.GROUP,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. BIOMED,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. BIOMED,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. BIOMED,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. DISTE.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. DISTE.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. DISTE.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Arthropod Born Viral Infections Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue